Hamed Gehad, Omar Hisham M, Sarhan Abbas M, Salah Hossam E
Department of Clinical Pathology, Faculty of Medicine, Zagazig University, Zagazig, Al-Sharkia, Egypt.
Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Zagazig University, Zagazig, Al-Sharkia, Egypt.
Int J Gen Med. 2022 Apr 20;15:4247-4258. doi: 10.2147/IJGM.S354092. eCollection 2022.
This study aimed to assess gene expression level as a prognostic marker in AML patients and to correlate the results with their clinical outcome.
This study was conducted on 50 de novo younger AML patients (median age 44). Quantitative real-time polymerase chain reaction (QRT-PCR) was used to assess the expression level of the gene. The transcription level of the target gene () was normalized to that of the reference gene (GAPDH). Twenty control samples were withdrawn from 20 age- and sex-matched individuals for the analysis of the results using the 2 method. On day 28 following induction chemotherapy, patients' bone marrow (BM) was examined for evaluation of their remission status.
gene expression was higher among AML patients who did not achieve complete remission (CR); also, it was higher in patients in the intermediate and poor cytogenetic risk groups. A significant positive correlation was found between PIM-2 level and BM blasts on day 28. In AML patients, PIM-2 has been discovered to be an independent predictive factor for achieving CR following standard induction treatment. Receiver operating characteristic curve (ROC) and area under the curve (AUC) were performed for PIM-2 level at diagnosis to evaluate its role in achieving remission after induction. It was found that PIM-2 at cutoff ≤1.6 had an AUC (0.903) with a sensitivity (90.48%) and specificity (86.21%), P <0.001.
Overexpression of the PIM-2 gene is associated with induction failure and low CR.
本研究旨在评估基因表达水平作为急性髓系白血病（AML）患者的预后标志物，并将结果与他们的临床结局相关联。
本研究对50例初发年轻AML患者（中位年龄44岁）进行。采用定量实时聚合酶链反应（QRT-PCR）评估该基因的表达水平。将目标基因（）的转录水平标准化为参考基因（GAPDH）的转录水平。从20名年龄和性别匹配的个体中抽取20份对照样本，采用2方法分析结果。在诱导化疗后第28天，检查患者的骨髓（BM）以评估其缓解状态。
未达到完全缓解（CR）的AML患者中基因表达较高；此外，在细胞遗传学风险为中危和高危组的患者中表达也较高。发现第28天时PIM-2水平与BM原始细胞之间存在显著正相关。在AML患者中，已发现PIM-2是标准诱导治疗后实现CR的独立预测因素。对诊断时的PIM-2水平进行受试者操作特征曲线（ROC）和曲线下面积（AUC）分析，以评估其在诱导后实现缓解中的作用。发现截断值≤1.6时的PIM-2的AUC为（0.903），敏感性为（90.48%），特异性为（86.21%），P<0.001。
PIM-2基因的过表达与诱导失败和低CR相关。
